News

Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at lower-volume facilities, according to recent…

The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have failed to respond to treatment.

  A man who calls himself a Hollyweed artist has started an Indiegogo crowdfunding campaign to create T-shirts marking California’s legalization of recreational marijuana — and…

Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…

A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…

People with chronic diseases value the Affordable Care Act (ACA), commonly known as Obamacare, more than Americans in general, a survey by PatientsLikeMe has found. They are also…

A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory multiple myeloma patients who also…

Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.

A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…

The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…